zoledronic acid has been researched along with Benign Monoclonal Gammopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batuman, O; Berenson, JR; Boccia, RV; Duvivier, H; Flam, M; Moezi, MM; Nassir, Y; Swift, RA; Wong, SF; Woytowitz, D; Yellin, O | 1 |
| Durnian, JM; Kyle, G; Olujohungbe, A | 1 |
1 trial(s) available for zoledronic acid and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Osteonecrosis; Radiography; Time Factors; X-Rays; Zoledronic Acid | 2008 |
1 other study(ies) available for zoledronic acid and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy.
Topics: Acute Disease; Conjunctivitis; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Uveitis, Anterior; Zoledronic Acid | 2005 |